Immunocellular therapeutics
This presentation is the property of its rightful owner.
Sponsored Links
1 / 31

ImmunoCellular Therapeutics PowerPoint PPT Presentation


  • 46 Views
  • Uploaded on
  • Presentation posted in: General

ImmunoCellular Therapeutics. Industry-leading, next-generation, cancer immunotherapy. November 2012. Disclaimer.

Download Presentation

ImmunoCellular Therapeutics

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Immunocellular therapeutics

ImmunoCellular Therapeutics

Industry-leading, next-generation, cancer immunotherapy

November 2012


Disclaimer

Disclaimer

This presentation contains certain “forward-looking statements” (statements as to matters other than historical facts) as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual events or results to differ materially from the events and include statements about our plans, objectives, expectations and intentions with respect to the potential for success of our scientific approach to cancer immunotherapy, clinical development efforts, operations, financial condition and other statements that are not historical in nature, particularly those that use terms such as “will,” “potential”, “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “projects,” “estimates” or similar language.

Important factors known to us that could cause actual results to differ materially from those expressed in such forward-looking statements include those set forth in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q and other reports filed with the SEC.

You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. The information in this presentation speaks only as of the date hereof, and except as required by law, we disclaim any obligation to update or revise any forward-looking statement.


Disruptive validated technology

Disruptive Validated Technology

Cancer Stem Cell Targeting

Potent Immunotherapy

+

= Effective Cancer Eradication


Why cancer v accines p reviously f ailed

Why Cancer Vaccines Previously Failed?

Problem

Solution

Minimal residual disease

Immune competent patients at diagnosis

Dendritic cells with persistent T-cell immune response

  • Late-stage disease

  • Immune compromised patients

  • Weak immune response

  • Target multiple antigens

  • Overall survival endpoint

  • Target cancer stem cells

  • Tumor mutation/escape

  • Flawed trial endpoints

  • Targeted tumor bulk


Immunocellular therapeutics

Without killing CSCs, it is like spraying for weeds without killing the roots. The weeds (tumors) come back.


Immunotherapy has a dvantages in targeting c ancer s tem c ells

Immunotherapy Has Advantages in Targeting Cancer Stem Cells

  • Immunotherapy can elicit T-cell mediated rejection of tumors

    • T cells are the way the body kills cancer cells

    • Improves specificity

    • Targets intracellular & surface antigens

    • Better safety profile

    • Differentiates between CSCs and normal stem cells

Antibodies only target CSC antigens on the surface of cancer cells

Cytotoxic T-cells target CSC antigens cancer presented by MHCs

Antibody

MHC

Antigen

Antigen

Cancer cell

Cancer cell

Cytotoxic T-cell


Product pipeline overview multiple therapies in different cancer indications

Product Pipeline OverviewMultiple therapies in different cancer indications

Active immunotherapies

  • ICT-107

    • Dendritic cell vaccine targeting glioblastoma antigens and CSCs

    • Phase I trial showed compelling clinical outcomes

    • Phase II study results anticipated late 2013

  • ICT-140

    • Dendritic cell vaccine targeting ovarian cancer antigens and CSCs

    • IND filing Q4/2012

  • ICT-121

    • Dendritic cell vaccine targeting CD133 (CSC marker)

    • IND approved; plan enrollment Q4/2012

      Antibody immunotherapies

  • Licensed to Caerus Molecular Discovery, funded by BioWa


Ict 107 preparation manufacturing multiple doses from only one apheresis procedure

ICT-107 Preparation & ManufacturingMultiple doses from only one apheresis procedure

GMP Manufacturing Facility

Shipovernight

Culture with cytokines

Apheresis

Apheresis

product

Peripheral blood mononuclear cells

Activated dendritic cells

Pulse w/ tumor-associated antigens

Patient

Intradermal injection

Shipback to physician

Aliquot & freeze

~30 doses

ICT-107

ICT-107


Immunocellular therapeutics

ICT-107 targets both tumor cells and CSCs


Ict 107 targets antigens overexpressed on glioblastoma cancer stem cells

ICT-107 Targets Antigens Overexpressed on Glioblastoma Cancer Stem Cells

ICT-107 targets six tumor antigens (nine amino acid epitopes that elicit an immune response in HLA-A1/A2 patients)


Immunocellular therapeutics

Expression of Tumor Antigens in GBM by RT-PCR

All GBM patients express three or more antigens

75% expressed all six

Patients from ICT-107 Phase I clinical trial


Phase i trial with ict 107

Phase I Trial with ICT-107

  • Patients received standard of care (surgery and chemo-radiation) followed by three vaccinations of ICT-107 every two weeks.

Nonrandomized, single-center study at Cedars-Sinai

  • 19 GBM patients

  • 16 newly diagnosed, 3 recurrent

  • ~75% fully resected


Pre and post operative mri scans of four gbm patients on ict 107

Pre- and Post-Operative MRI Scans of Four GBM Patients on ICT-107


Ict 107 phase i results newly diagnosed gbm patients efficacy and safety

ICT-107 Phase I ResultsNewly diagnosed GBM patients (efficacy and safety)

RT/Chemo

Vaccine

Progressive disease

Historical

Fully-resected

ICT-107

Six patients without recurrence for over 4 years (3 of them over 5 years)

No Grade 3 or 4 toxicities.

Adverse events (Grade 1 or 2) include diarrhea, fatigue, flushing, pruritis, rash, vomiting

= Death

Stupp et al. N Engl J Med. 2005 Mar 10;352(10):987-96 & Stupp et al.LancetOncol. 2009 May;10(5):459-66.


Ict 107 improves s urvival in gbm

ICT-107 Improves Survival in GBM

Progression Free Survival (PFS)

Overall Survival (OS)

ICT-107

ICT-107

Historical standard of care

Historical standard of care

  • Significant increase in median PFS

    • 16.9 months for ICT-107

    • 6.9 months for historical SoC*

  • Significant increase in median OS

    • 38.4 months for ICT-107

    • 14.6 months for historical SoC*

*Surgery followed by radiation and temozolomide (TMZ). Stupp et al. N Engl J Med. 2005 Mar 10;352(10):987-96.


Correlation of pfs and os with antigen expression

Correlation of PFS and OS with Antigen Expression


Cd133 expression csc biomarker p rimary recurrent tumor samples from the same patient

CD133 Expression (CSC Biomarker)Primary & recurrent tumor samples from the same patient

Phuphanich et al. Cancer Immunol Immunother. 2012 Jul 31.


Ict 107 phase ii trial design randomized placebo controlled double blind trial

ICT-107 Phase II Trial DesignRandomized, placebo-controlled, double-blind trial

  • 123 patients treated at 25 centers

    • HLA-A1/A2 50-75% of US population

  • 278 patients enrolled

  • Primary endpoint: OS

  • Secondary endpoints:

    • PFS

    • OS/PFS at various time intervals

    • Immune response (T-cells)

    • Safety

  • Interim analysis (based on 50% events) in Q1/2013

  • Final results in 2H2013

  • Derisked by improving DC function, timing, frequency

  • ICT-107 +

    TMZ

    Newly Diagnosed GBM Patients (n=123)

    2:1 randomization

    Placebo

    Unloaded DCs + TMZ

    Surgery

    Apheresis

    Vaccinations

    Radiation

    TMZ

    7 weeks

    6 weeks

    4 weeks

    4 weeks

    4 weeks

    4 weeks

    4 weeks


    Ict 107 phase ii trial enrollment 25 clinical trial sites 278 patients enrolled

    ICT-107 Phase II Trial Enrollment25 clinical trial sites – 278 patients enrolled

    • Johns Hopkins University

    • New York University

    • University of Texas at Houston

    • Northwestern University

    • Arizona Cancer Center

    • New Jersey Neuroscience Institute

    • UC San Diego

    • Moffitt Cancer Center

    • Penn State

    • University of Pennsylvania

    • University of Virginia

    • Wake Forest

    • Cornell Presbyterian

    • Massachusetts General

    • Kentuckiana Cancer Institute

    • Cedars-Sinai Medical Center

    • University Hospital Case Medical Center

    • Rush University

    • Overlook Hospital

    • Baylor University

    • Cleveland Clinic

    • University of Alabama

    • Thomas Jefferson

    • Long Island Brain Center


    Fda approvals newly diagnosed gbm

    FDA ApprovalsNewly Diagnosed GBM

    Gliadel

    • Approval in 2003

    • Double-blind, placebo-controlled, randomized Phase III trial showing 13.8 vs. 11.6 month survival

      Temozolomide

    • Approval in 2005

    • Double-blind, placebo-controlled, randomized Phase III trial showing 14.6 vs. 12.1 month survival


    Projected costs ict 107 vs provenge lower cost of goods better logistics

    Projected Costs: ICT-107 vs. ProvengeLower cost of goods, better logistics

    Source: Quarterly earnings transcripts and public filings.


    Other immunotherapy candidates

    Other Immunotherapy Candidates


    Ict 140 ovarian cancer vaccine

    ICT-140: Ovarian Cancer Vaccine

    Ovarian cancer is similar to GBM

    • Minimal residual disease after surgery

    • Immuno-responsive

      Dendritic cell vaccine targeting CSCs

    • Seven antigens over-expressed in ovarian cancer, including three antigens used in ICT-107

      • HER2/neu, IL-13Rα2, MAGE1, mesothelin, EphA2, & two more antigens

    • File IND by Q4/2012


    Ict 121 csc targeted universal vaccine

    ICT-121: CSC-targeted Universal Vaccine

    • Dendritic cell vaccine loaded with two CD133 peptides

    • CD133 is highly expressed on CSCs

    • CD133 is expressed on most solid tumors, including brain, colon, non-small cell lung, melanoma, pancreatic, and breastcancer

    • Initial indication in recurrent GBM

    • PI-sponsored Phase I trial at Cedars-Sinai Medical Center

      • 20 patients

      • IND approved; plan

        enrollment Q4/2012


    Inverse correlation between cd133 expression with survival on gliomas

    Inverse Correlation between CD133 Expression with Survival on Gliomas

    CD133 expression correlates inversely with grade II to IV glioma patient survival time. The survival time calculated from the day of operation was plotted against the percentage of CD133+ cells in the CD45-cell fraction from the specimens of each patient. UD: undetectable CD133 expression. Bold black bars indicate the median survival time for patients in groups with CD133+ cells either lower or higher than 30% of total CD45-cells.

    Source: Rebetz et al. PLoS ONE. 2008.


    Strong ip position

    Strong IP Position

    28+ patents and patent applications

    • 10 patents issued or allowed

    • 18+ patents pending

      Vaccine patents and applications include

    • Method of use for six antigen vaccine (ICT-107)

    • Manufacturing process for production of ICT-107

    • Use of dendritic cells with chemotherapy for neural cancers

    • Immunotherapy targeting IL-13Rα2

    • Immunotherapy targeting CD133

      Issued patents on monoclonal antibodies cover composition of matter, therapeutic treatments and diagnostics


    Experienced management team

    Experienced Management Team

    Experience in developing over 20 products in cell & gene therapy and vaccines

    John Yu, MD, Chairman & CSO, Interim CEO

    • Neurosurgeon at Cedars-Sinai, Mass General Hospital, Harvard Medical School

      Elma Hawkins, PhD, Head of Clinical Development

    • Antigenics, Genzyme, Warner Lambert/Parke Davis

      Jim Bender, PhD, MPH, VP of Manufacturing & Product Development

    • IDM Pharma, Baxter Healthcare

      David Fractor, CPA, CFO

    • HemaCare, Andwin, Deloitte & Touche

      Peter Ho, PhD, Director of Business Development

    • Grey Healthcare Group, Prudential Equity Group, Allergan, D.E. Shaw


    Product pipeline

    Product Pipeline

    2011

    2012

    2013

    2014

    Q1

    Q2

    Q3

    Q4

    Q1

    Q2

    Q3

    Q4

    Q1

    Q2

    Q3

    Q4

    Q1

    Q2

    Q3

    Q4

    Phase II trial

    ICT-107

    New GBM

    Interim analysis

    Final results

    Preclinical

    Phase I/II trial

    ICT-140

    Ovarian

    IND

    Preclinical

    Phase I trial

    ICT-121

    Recurrent GBM

    IND


    Recent upcoming milestones

    Recent & Upcoming Milestones

    May 2012

    NYSE MKT listing

    July 2012

    ICT-121 IND

    October 2013

    SITC abstract

    October 2012

    SITC abstract

    2H 2013

    ICT-107 Ph 2 final

    December 2012

    ICT-121 Ph 1

    Q3 2013

    ICT-140 Ph 1/2

    June 2013

    ASCO abstract

    November 2013

    SNO abstract

    Q1 2013

    ICT-107 Ph 2 interim

    ICT-140 IND

    November 2012

    SNO abstract

    August 2012

    ICT-107 Ph 2 enrollment


    Strong financial position capitalization

    Strong Financial Position & Capitalization


    Immunocellular therapeutics1

    ImmunoCellular Therapeutics

    Industry-leading, next-generation, cancer immunotherapy

    November 2012


  • Login